ArticleBMC complementary medicine and therapies2025
Isorhamnetin protects against D-GalN/LPS-induced acute liver injury in mice through anti-oxidative stress, anti-inflammation, and anti-apoptosis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Protective effects ofRedox report : communications in free radical research · 2026Article
- Ergothioneine Ameliorates Alcoholic Fatty Liver Disease: A Dual Strategy of Accelerated Ethanol Elimination and Reducing Oxidative Stress.Journal of biochemical and molecular toxicology · 2026Article
- Research progress on active ingredients of traditional Chinese medicine in the treatment of asthenozoospermia.Frontiers in reproductive health · 2026Review
- Modulation of Behavioral, Biochemical, Immunomodulatory, and Transcriptional Profiles by the StrainInternational journal of molecular sciences · 2025Article
- Butein mitigates 5-FU-triggered hepatotoxicity via antioxidant, anti-inflammatory, and anti-apoptotic pathways.Toxicology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute liver injury (ALI), which can progress to cirrhosis, hepatocellular carcinoma and acute liver failure, has become a global concern and a serious threat to human life and health. Isorhamnetin (ISO) is an O-methylated flavonol from the class of flavonoids. It has a protective effect on various organs, but its effect on ALI is still unclear in current studies. PURPOSE: This study aimed to investigate the protective effect of ISO against D-galactosamine (D-GalN)/lipopolysaccharide (LPS)-induced ALI and to explore the underlying molecular mechanisms.
methodsNinety-six male Kunming mice were randomly divided into six groups and given the appropriate drug administration for 14 days. The ALI mouse model was established by intraperitoneal injection of 700 mg/kg D-GalN and 10 µg/kg LPS. Hematoxylin-eosin (HE) staining was performed to observe the histopathological changes. Enzyme-linked immunosorbent assay (ELISA) and quantitative Real-time Polymerase Chain Reaction (qRT-PCR) were performed to detect the expression of genes related to oxidative stress and inflammation. Inflammation and apoptosis related factors were detected by western blot.
resultsISO alleviated D-GalN/LPS-induced ALI, reducing the alanine transaminase (ALT), aspartate transaminase (AST), and malondialdehyde (MDA) levels (P < 0.01), while improving histopathology (P < 0.05). Additionally, ISO elevated the superoxide dismutase (SOD) level, and improved the survival rate of mice (P < 0.01). Moreover, ISO reduced the nitric oxide (NO), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) levels (P < 0.05), while increasing the glutathione (GSH), and catalase (CAT) levels (P < 0.05). ISO also decreased the expression of nuclear factor-kappa B alpha (IκBα), Nuclear factor kappa-B (NF-κB) p65, IL-1β, IL-6, TNF-α, nitric oxide synthase (iNOS), and toll-like receptor 4 (TLR4) at the messenger ribonucleic acid (mRNA) level (P < 0.05). Furthermore, western blot showed that ISO decreased the expression of NF-κB p-p65, cysteine aspartate protease-3 (caspase-3), and B-cell lymphoma 2-associated X protein (Bax) proteins and elevated the expression of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma 2-like protein (Bcl-xL) proteins (P < 0.05).
conclusionsISO could alleviate D-GalN/LPS-induced ALI by attenuating oxidative stress and inflammatory cytokines, enhancing the expression of anti-apoptotic proteins, reducing hepatocyte apoptosis, and inhibiting the activation of the NF-κB signaling pathway. Our study will provide some new references for treating ALI with ISO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.